U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Jun 26 16:52:11 UTC 2021
Edited
by admin
on Sat Jun 26 16:52:11 UTC 2021
Protein Sub Type
Sequence Type COMPLETE
Record UNII
NQI5D806LC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-HYDROXYTRYPTAMINE RECEPTOR 2A
Common Name English
5-HT2A
Common Name English
HTR2
Common Name English
5-HT-2
Common Name English
SEROTONIN RECEPTOR 2A
Common Name English
5-HT2A RECEPTOR
Common Name English
Code System Code Type Description
UNIPROT
P28223
Created by admin on Sat Jun 26 16:52:19 UTC 2021 , Edited by admin on Sat Jun 26 16:52:19 UTC 2021
PRIMARY
FDA UNII
NQI5D806LC
Created by admin on Sat Jun 26 16:52:19 UTC 2021 , Edited by admin on Sat Jun 26 16:52:19 UTC 2021
PRIMARY
PHAROS
P28223
Created by admin on Sat Jun 26 16:52:19 UTC 2021 , Edited by admin on Sat Jun 26 16:52:19 UTC 2021
PRIMARY
From To
1_148 1_227
1_349 1_353
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_8
N 1_38
N 1_44
N 1_51
N 1_54
Related Record Type Details
INVERSE AGONIST->TARGET
AGONIST -> TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR
Ki
AGONIST -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
MAJOR
Ki
RADIOLIGAND->TARGET
RADIOLIGAND->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
all of the tryptamines, including DMT but with the exception of psilocin, were more potent agonists at the 5-HT2A receptor than LSD in the assay that was used in the present study. LSD and psilocin were 5-HT2A receptor partial agonists, with 28% and 16% activation efficacy, respectively, whereas all of the other compounds presented higher 5-HT2A receptor activation efficacies (up to >80% for DiPT and 5-MeO-MiPT).
EC50
ANTAGONIST->TARGET
INHIBITOR -> TARGET
RADIOLIGAND->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
RADIOLIGAND->TARGET
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
WEAK INHIBITOR->TARGET
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
RADIOLIGAND->TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
ANTAGONIST->TARGET
BINDING
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
cell:CHO; ligand: 3-H-KETASERIN
BINDING
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
Ki
INVERSE AGONIST->TARGET
AGONIST
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
PARTIAL AGONIST->TARGET
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
RADIOLIGAND->TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL
Molecular Formula CHEMICAL